Meitheal Pharmaceuticals Revenue, Growth & Competitor Profile

Company Profile & Annual Report for Meitheal Pharmaceuticals

Access the complete profile.

Meitheal Pharmaceuticals Fast Facts

Revenue	$10 - $100 million    See Exact Annual Revenue
Employees	10 - 100Exact Company Size
Primary Industry	325411 Medicinal & Botanical Manufacturing
Additional NAICS Codes	325412 Pharmaceutical Preparation Manufacturing
Address	8700 W. Bryn Mawr Avenue Suite 600s Chicago, IL 60631

Note: Revenues for privately held companies are statistical evaluations.


Meitheal Pharmaceuticals's Annual Report & Profile shows critical firmographic facts:

• What is the company's size? (Annual sales and employees)
  • Meitheal Pharmaceuticals's annual revenues are $10 - $100 million (see exact revenue data)
• What industry is the company in?
  • Meitheal Pharmaceuticals is classified as operating in the Medicinal & Botanical Manufacturing industry, NAICS Code 325411.

Meitheal Pharmaceuticals Annual Revenue and Growth Rate

Meitheal Pharmaceuticals	Revenue Est. ($ Million)	Growth Rate (%)	# Employees
2023	$10 - $100 million Details in Premium Report
2022
2021
2020
2019

1-Year Growth Rate: 3-Year Growth Rate (CAGR):

Note: Meitheal Pharmaceuticals's revenues are gauged from an analysis of company filings.

Meitheal Pharmaceuticals's Income Statement (based on Industry Averages)

Meitheal Pharmaceuticals P&L	$ Millions
Revenue (Sales)
Cost of Goods Sold
Gross Profit
Operating Expenses
Advertising
Salaries and wages
Other Operating Expenses
Total Operating Expenses
Operating Income
EBITDA
EBIT (Earnings Before Interest and Taxes)
Net Profit

Trademark Applications

Trademark applications show the products and services that Meitheal Pharmaceuticals is developing and marketing. Meitheal Pharmaceuticals's new tradmarks suggest it is investing in R&D and marketing, while expanding into new products or markets. Trademarks may include brand names, product names, logos and slogans.

Trademark	Date
MEITHEAL FERTILITY Pharmaceutical products; injectable pharmaceutical products; fertility enhancing pharmaceutical products; fertility enhancing injectable pharmaceutical products; pharmaceutical products to enhance fertility; pharmaceutical products to prevent premature ovulation; gonadotropin-releasing hormone antagonists; pharmaceutical products to block the effects of gonadotropin-releasing hormones; pharmaceutical products for controlling the secretion of luteinizing hormones; pharmaceutical products for controlling ovulation; pharmaceutical products for the treatment of gynecological disorders and fertility problems; pharmaceutical products for inhibition of premature luteinizing hormones surges in women undergoing controlled ovarian stimulation	09/13/2023
ANIVIO house mark for a full line of biologic, biosimilar, and pharmaceutical preparations; biologics; biosimilars; pharmaceuticals; biologic, biosimilar, and pharmaceutical preparations; biologic, biosimilar, and pharmaceutical products; anti-TNF alpha antibodies; monoclonal antibodies; anti-inflammatories; anti-inflammatory biologic, biosimilar, and pharmaceutical preparations; biologic, biosimilar, and pharmaceutical preparations for the treatment of lung diseases and disorders; biologic, biosimilar, and pharmaceutical preparations for the treatment of inflammatory disorders; biologic, biosimilar, and pharmaceutical preparations for the treatment of pulmonary sarcoidosis; biologic, biosimilar, and pharmaceutical preparations for the treatment of sarcoidosis; biologic, biosimilar, and pharmaceutical preparations to reduce or prevent granulomas; biologic, biosimilar, and pharmaceutical preparations to reduce or prevent fibrosis; biologic, biosimilar, and pharmaceutical preparations, namely, biopharmaceuticals based on human monoclonal antibodies for the treatment of inflammatory diseases and disorders; self-replicating mRNA; pharmaceutical preparations containing self-replicating mRNA; pharmaceutical preparations containing self-replicating mRNA for the treatment of lung diseases and disorders, inflammatory disorders, pulmonary sarcoidosis, sarcoidosis; pharmaceutical preparations containing self-replicating mRNA to reduce or prevent granulomas; pharmaceutical preparations containing self-replicating mRNA to reduce or prevent fibrosis	09/11/2023

See all trademarks and details in the Full Report.

Market Share of Meitheal Pharmaceuticals's Largest Competitors

A competitive analysis shows these companies are in the same general field as Meitheal Pharmaceuticals, even though they may not compete head-to-head. These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines. The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies. Competitive advantage comes from offering better pricing or superior products/service.

Company	Headquarters	Revenue ($ MM)
XYMOGEN	Orlando, FL	100
AVANTI NUTRITIONAL LABORATORIES	Miami Lakes, FL	37
NUTRITION FORMULATORS	Miramar, FL	36
RTPR	Cabot, AR	33
INTEGRATED BOTANICS	Fort Worth, TX	29
COSMAX NBT USA	Garland, TX	29
CJB INDUSTRIES	Valdosta, GA	28
ALTERNATIVE LABORATORIES	Naples, FL	28
S&B PHARMA	Azusa, CA	28

Nearby Competitors

These companies are similar in business line and location to Meitheal Pharmaceuticals. While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.

Company	Headquarters	Revenue ($ MM)
JDRC MANAGED SERVICES	Chicago, IL	100
PARAGON BIOSCIENCES	Chicago, IL	5
MEITHEAL PHARMACEUTICALS	Chicago, IL	2
BAJAJ MEDICAL	Chicago, IL	2
ADELLO BIOLOGICS	Chicago, IL	1
CHOICE HEALTHCARE SOLUTIONS US	Chicago, IL	0

Future Competition: Meitheal Pharmaceuticals's Fastest Growing Competitors

These companies are in the same general field as Meitheal Pharmaceuticals and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.

Company	Revenue ($ MM)